Other FDA-approved therapies, such as glucocorticoids, dasatinib (a tyrosine kinase inhibitor), and guratimod (an anti-rheumatic drug), have also been suggested to inhibit the NF-κB axis in cancer and may have a potential role in future development for CRC patients, revised in [72]. The gene discussed is NFKB1; the disease is colorectal carcinoma.